The role of cetuximab as first-line treatment of colorectal liver metastases

HPB

Volumn 15, Issue 1, 2013, Pages 11-17

  Jones, Claire ^a,b   Taylor, Mark A ^b   McWilliams, Billy ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACNE; ADD ON THERAPY; ASTHENIA; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PARESTHESIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VOMITING; WILD TYPE;

EID: 84870895981     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00591.x     Document Type: Conference Paper

References (20)

1. Office for National Statistics. Cancer registrations in England 2008. 21 October 2010. Available at: http://www.statistics.gov.uk/statbase/Product.asp? vlnk=8843 (last accessed 18 June 2011).
2. Geoghegan JG, Scheele J,. (1999) Treatment of colorectal liver metastases. Br J Surg 86: 158-169.
3. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al,. (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10: 663-669.
4. McGrath JP, Capon DJ, Smith DH, Chen EY, Seeburg PH, Goeddel DV, et al,. (1999) Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 304: 501-506.
5. Satlz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al,. (2007) Randomised phase II trial of cetuximab, bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25: 4557-4561.
6. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, et al,. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450-456.
7. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, et al,. (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25: 5225-5232.
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de, Braud F, et al,. (2009) Fluorouracil, leucovorin and oxaliplatin with or without cetuximab in the first line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
9. Bokemeyer C, Bondarenko I, Hartmann JT, de, Braud F, Schuch G, Zubel A, et al,. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.
10. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al,. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncology 11: 38-47.
11. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al,. (2009) Cetuximab and chemotherapy as an initial treatment of metastatic colorectal cancer. NEJM 360: 1408-1417.
12. Van Cutsem E, Kohne CH, Lang I, Folpreht G, Nowacki MP, Cascinu S, et al,. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumour KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019.
13. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al,. (2010) Cetuximab and FOLFOX 6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16: 3133-3143.
14. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al,. (2010) Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103: 1542-1547.
15. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al,. (2011) Addition of cetuximab to oxaliplatin-basec first line combination chemotherapy for the treatment of advanced colorectal cancer: results of a randomized phase 3 MRC COIN trial. Lancet 377: 2103-2114.
16. Adams R, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al,. (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet Oncology 12: 642-653.
17. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, et al,. (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss group for clinical cancer research SAKK. Ann Oncol 19: 1288-1292.
18. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, et al,. (2008) A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19: 734-738.
19. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al,. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. NEJM 360: 563-572.
20. Kopetz S, Cahng GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al,. (2009) Improved survival in metastatic colorectal cancer is associated with the adoption of hepatic resection and improved chemotherapy. Journal of Clin Oncology 27: 3677-3683.